Targeting the IL17 pathway for the prevention of graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 752-759

  Van der Waart, Anniek B ^a,b   van der Velden, Walter J F M ^a   Blijlevens, Nicole M ^a   Dolstra, Harry ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allogeneic stem cell transplantation; Danger associated molecular patterns (DAMP); Dendritic cell; GVHD; Interleukin 17; Pathogen associated molecular patterns (PAMP); Th17 cell

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; LECTIN RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PATTERN RECOGNITION RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ALLOGENEIC STEM CELL TRANSPLANTATION; CELL EXPANSION; CYTOKINE PRODUCTION; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMACYTOID DENDRITIC CELL; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TISSUE INJURY; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; PROCEDURES; T LYMPHOCYTE;

ANIMALS; DENDRITIC CELLS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-17; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84899902498     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.02.007     Document Type: Review

References (98)

1. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
2. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
3. Hill G.R., Teshima T., Gerbitz A., et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999, 104:459-467.
4. Penack O., Holler E., van den Brink M.R. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood 2010, 115:1865-1872.
5. Nikolic B., Lee S., Bronson R.T., Grusby M.J., et al. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000, 105:1289-1298.
6. Bossard C., Malard F., Arbez J., et al. Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. Leukemia 2012, 26:1471-1474.
7. Carlson M.J., West M.L., Coghill J.M., et al. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009, 113:1365-1374.
8. Dander E., Balduzzi A., Zappa G., et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 2009, 88:1261-1272.
9. van der Waart A.B., van der Velden W.J., van Halteren A.G., et al. Decreased levels of circulating IL17-producing CD161+CCR6+ T cells are associated with graft-versus-host disease after allogeneic stem cell transplantation. PLoS One 2012, 7:e50896.
10. Koenen H.J., Smeets R.L., Vink P.M., et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
11. Ivanov, McKenzie B.S., Zhou L., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
12. Durant L., Watford W.T., Ramos H.L., et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 2010, 32:605-615.
13. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
14. Wilson N.J., Boniface K., Chan J.R., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
15. Langrish C.L., Chen Y., Blumenschein W.M., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
16. Zhou L., Ivanov, Spolski R., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
17. Elias K.M., Laurence A., Davidson T.S., et al. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 2008, 111:1013-1020.
18. Veldhoen M., Hirota K., Westendorf A.M., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453:106-109.
19. Weaver C.T., Elson C.O., Fouser L.A., Kolls J.K. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol 2013, 8:477-512.
20. Ersvaer E., Melve G.K., Bruserud O. Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?. Cancer Immunol Immunother 2011, 60:1669-1681.
21. Kappel L.W., Goldberg G.L., King C.G., et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009, 113:945-952.
22. Yi T., Zhao D., Lin C.L., et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 2008, 112:2101-2110.
23. Yi T., Chen Y., Wang L., et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009, 114:3101-3112.
24. Yu Y., Wang D., Liu C., et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORgammat in mice. Blood 2011, 118:5011-5020.
25. Fulton L.M., Carlson M.J., Coghill J.M., et al. Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORgammat. J Immunol 2012, 189:1765-1772.
26. Billerbeck E., Kang Y.H., Walker L., et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A 2010, 107:3006-3011.
27. Hanash A.M., Dudakov J.A., Hua G., et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012, 37:339-350.
28. Caproni M., Antiga E., Melani L., et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009, 29:210-214.
29. Geboes L., Dumoutier L., Kelchtermans H., et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009, 60:390-395.
30. Couturier M., Lamarthee B., Arbez J., et al. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect. Leukemia 2013, 27:1527-1537.
31. Liu Y., Cai Y., Dai L., et al. The expression of Th17-associated cytokines in human acute graft-versus-host disease. Biol Blood Marrow Transplant 2013, 19:1421-1429.
32. Elmaagacli A.H., Koldehoff M., Landt O., Beelen D.W. Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant 2008, 41:821-826.
33. Gruhn B., Intek J., Pfaffendorf N., et al. Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 2009, 15:1571-1577.
34. Broady R., Yu J., Chow V., et al. Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. Blood 2010, 116:5748-5751.
35. Nistala K., Adams S., Cambrook H., et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci U S A 2010, 107:14751-14756.
36. Maggi L., Santarlasci V., Capone M., et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 2010, 40:2174-2181.
37. Broen K., van der Waart A.B., Greupink-Draaisma A., et al. Polymorphisms in CCR6 are associated with chronic graft-versus-host disease and invasive fungal disease in matched-related hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1443-1449.
38. Schutyser E., Struyf S., Van D.J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003, 14:409-426.
39. Hirata T., Osuga Y., Takamura M., et al. Recruitment of CCR6-expressing Th17 cells by CCL 20 secreted from IL-1 beta-, TNF-alpha-, and IL-17A-stimulated endometriotic stromal cells. Endocrinology 2010, 151:5468-5476.
40. Schmuth M., Neyer S., Rainer C., et al. Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 2002, 11:135-142.
41. Piper K.P., Horlock C., Curnow S.J., et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood 2007, 110:3827-3832.
42. Croudace J.E., Inman C.F., Abbotts B.E., et al. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood 2012, 120:4246-4255.
43. Olsen T., Rismo R., Cui G., et al. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine 2011, 56:633-640.
44. Shen W., Durum S.K. Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease. Neurochem Res 2010, 35:940-946.
45. Ratajczak P., Janin A., Peffault de L.R., et al. Th17/Treg ratio in human graft-versus-host disease. Blood 2010, 116:1165-1171.
46. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
47. Stenger E.O., Turnquist H.R., Mapara M.Y., Thomson A.W. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood 2012, 119:5088-5103.
48. Vakkila J., Thomson A.W., Hovi L., et al. Circulating dendritic cell subset levels after allogeneic stem cell transplantation in children correlate with time post transplant and severity of acute graft-versus-host disease. Bone Marrow Transplant 2005, 35:501-507.
49. Isaksson M., Ardesjo B., Ronnblom L., et al. Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE. Eur J Immunol 2009, 39:2925-2935.
50. Yu C.F., Peng W.M., Oldenburg J., et al. Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J Immunol 2010, 184:1159-1167.
51. Turtle C.J., Delrow J., Joslyn R.C., et al. Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161hi CD8{alpha}+ semi-invariant T cells. Blood 2011, 118:2752-2762.
52. Sisirak V., Vey N., Vanbervliet B., et al. CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood 2011, 118:5130-5140.
53. Lande R., Gregorio J., Facchinetti V., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
54. Gilliet M., Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol 2008, 20:401-407.
55. Frohm M., Agerberth B., Ahangari G., et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997, 272:15258-15263.
56. Joffre O.P., Sancho D., Zelenay S., et al. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur J Immunol 2010, 40:1255-1265.
57. Poulin L.F., Reyal Y., Uronen-Hansson H., et al. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood 2012, 119:6052-6062.
58. Ahrens S., Zelenay S., Sancho D., et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 2012, 36:635-645.
59. Murphy S., Nguyen V.H. Role of gut microbiota in graft-versus-host disease. Leuk Lymphoma 2011, 52:1844-1856.
60. Zeiser R., Penack O., Holler E., Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med (Berl) 2011, 89:833-845.
61. Jones J.M., Wilson R., Bealmear P.M. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res 1971, 45:577-588.
62. van Bekkum D.W., Roodenburg J., Heidt P.J., van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974, 52:401-404.
63. Jenq R.R., Ubeda C., Taur Y., et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012, 209:903-911.
64. Akpek G., Joseph R., Gunay C., et al. Frequent detection of herpes simplex virus antigen in skin and peripheral blood CD34+ mononuclear cells from patients with graft-versus-host disease. Biol Blood Marrow Transplant 2013, 19:529-537.
65. Cantoni N., Hirsch H.H., Khanna N., et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:1309-1314.
66. Beelen D.W., Elmaagacli A., Muller K.D., et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999, 93:3267-3275.
67. van der Velden W.J., Netea M.G., de Haan A.F., et al. Role of the mycobiome in human acute graft-versus-host disease. Biol Blood Marrow Transplant 2013, 19:329-332.
68. Marr K.A., Seidel K., Slavin M.A., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000, 96:2055-2061.
69. Brandon J.A., Jennings C.D., Kaplan A.M., Bryson J.S. Development of a T(H)17 immune response during the induction of murine syngeneic graft-versus-host disease. Cytokine 2010, 52:265-273.
70. Kullberg M.C., Andersen J.F., Gorelick P.L., et al. Induction of colitis by a CD4+ T cell clone specific for a bacterial epitope. Proc Natl Acad Sci U S A 2003, 100:15830-15835.
71. Jankovic D., Ganesan J., Bscheider M., et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med 2013, 210:1899-1910.
72. Dusseaux M., Martin E., Serriari N., et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 2011, 117:1250-1259.
73. Smeekens S.P., van de Veerdonk F.L., van der Meer J.W., et al. The Candida Th17 response is dependent on mannan-and beta-glucan-induced prostaglandin E2. Int Immunol 2010, 22:889-895.
74. Jarrossay D., Napolitani G., Colonna M., et al. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001, 31:3388-3393.
75. Bauer S., Kirschning C.J., Hacker H., et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001, 98:9237-9242.
76. Parcina M., Wendt C., Goetz F., et al. Staphylococcus aureus-induced plasmacytoid dendritic cell activation is based on an IgG-mediated memory response. J Immunol 2008, 181:3823-3833.
77. Min C.K., Lee W.Y., Min D.J., et al. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 28:935-940.
78. Visentainer J.E., Lieber S.R., Persoli L.B., et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol 2003, 31:1044-1050.
79. Liem L.M., van Houwelingen H.C., Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998, 66:863-871.
80. Sakata N., Yasui M., Okamura T., et al. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant 2001, 27:1153-1161.
81. Cho B.S., Lim J.Y., Yahng S.A., et al. Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation. Ann Hematol 2012, 91:439-448.
82. Espinoza J.L., Takami A., Nakata K., et al. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One 2011, 6:e26229.
83. Hanash A.M., Kappel L.W., Yim N.L., et al. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood 2011, 118:446-455.
84. Hippen K.L., Bucher C., Schirm D.K., et al. Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood 2012, 119:619-628.
85. Bucher C., Koch L., Vogtenhuber C., et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood 2009, 114:5375-5384.
86. Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
87. Bayraktar U.D., de Lima M., Saliba R.M., et al. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2013, 19:898-903.
88. Huh J.R., Leung M.W., Huang P., et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature 2011, 472:486-490.
89. Church L.D., McDermott M.F. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009, 11:81-89.
90. Antin J.H., Weisdorf D., Neuberg D., et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002, 100:3479-3482.
91. Chen X., Das R., Komorowski R., et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009, 114:891-900.
92. Tawara I., Koyama M., Liu C., et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 2011, 17:77-88.
93. Pesce B., Soto L., Sabugo F., et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol 2013, 171:237-242.
94. Leonardi C., Matheson R., Zachariae C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-1199.
95. Papp K.A., Leonardi C., Menter A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189.
96. Hueber W., Sands B.E., Lewitzky S., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700.
97. Pidala J., Perez L., Beato F., Anasetti C. Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD. Bone Marrow Transplant 2012, 47:747-748.
98. Wada Y., Cardinale I., Khatcherian A., et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One 2012, 7:e35069.